HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Inter-observer agreement for the histological diagnosis of invasive lobular breast carcinoma.

Abstract
Invasive lobular breast carcinoma (ILC) is the second most common breast carcinoma (BC) subtype and is mainly driven by loss of E-cadherin expression. Correct classification of BC as ILC is important for patient treatment. This study assessed the degree of agreement among pathologists for the diagnosis of ILC. Two sets of hormone receptor (HR)-positive/HER2-negative BCs were independently reviewed by participating pathologists. In set A (61 cases), participants were provided with hematoxylin/eosin (HE)-stained sections. In set B (62 cases), participants were provided with HE-stained sections and E-cadherin immunohistochemistry (IHC). Tumor characteristics were balanced. Participants classified specimens as non-lobular BC versus mixed BC versus ILC. Pairwise inter-observer agreement and agreement with a pre-defined reference diagnosis were determined with Cohen's kappa statistics. Subtype calls were correlated with molecular features, including CDH1/E-cadherin mutation status. Thirty-five pathologists completed both sets, providing 4,305 subtype calls. Pairwise inter-observer agreement was moderate in set A (median κ = 0.58, interquartile range [IQR]: 0.48-0.66) and substantial in set B (median κ = 0.75, IQR: 0.56-0.86, p < 0.001). Agreement with the reference diagnosis was substantial in set A (median κ = 0.67, IQR: 0.57-0.75) and almost perfect in set B (median κ = 0.86, IQR: 0.73-0.93, p < 0.001). The median frequency of CDH1/E-cadherin mutations in specimens classified as ILC was 65% in set A (IQR: 56-72%) and 73% in set B (IQR: 65-75%, p < 0.001). Cases with variable subtype calls included E-cadherin-positive ILCs harboring CDH1 missense mutations, and E-cadherin-negative ILCs with tubular elements and focal P-cadherin expression. ILCs with trabecular growth pattern were often misclassified as non-lobular BC in set A but not in set B. In conclusion, subtyping of BC as ILC achieves almost perfect agreement with a pre-defined reference standard, if assessment is supported by E-cadherin IHC. CDH1 missense mutations associated with preserved E-cadherin protein expression, E- to P-cadherin switching in ILC with tubular elements, and trabecular ILC were identified as potential sources of discordant classification.
AuthorsMatthias Christgen, Leonie Donata Kandt, Wiebke Antonopoulos, Stephan Bartels, Mieke R Van Bockstal, Martin Bredt, Maria Jose Brito, Henriette Christgen, Cecile Colpaert, Bálint Cserni, Gábor Cserni, Maximilian E Daemmrich, Raihanatou Danebrock, Franceska Dedeurwaerdere, Carolien Hm van Deurzen, Ramona Erber, Christine Fathke, Henning Feist, Maryse Fiche, Claudia Aura Gonzalez, Natalie D Ter Hoeve, Loes Kooreman, Till Krech, Glen Kristiansen, Janina Kulka, Florian Laenger, Marcel Lafos, Ulrich Lehmann, Maria Dolores Martin-Martinez, Sophie Mueller, Enrico Pelz, Mieke Raap, Alberto Ravarino, Tanja Reineke-Plaass, Nora Schaumann, Anne-Marie Schelfhout, Maxim De Schepper, Jerome Schlue, Koen Van de Vijver, Wim Waelput, Axel Wellmann, Monika Graeser, Oleg Gluz, Sherko Kuemmel, Ulrike Nitz, Nadia Harbeck, Christine Desmedt, Giuseppe Floris, Patrick Wb Derksen, Paul J van Diest, Anne Vincent-Salomon, Hans Kreipe
JournalThe journal of pathology. Clinical research (J Pathol Clin Res) Vol. 8 Issue 2 Pg. 191-205 (03 2022) ISSN: 2056-4538 [Electronic] England
PMID34889530 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2021 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland & John Wiley & Sons, Ltd.
Chemical References
  • Biomarkers, Tumor
Topics
  • Biomarkers, Tumor (genetics, metabolism)
  • Breast Neoplasms (diagnosis, genetics, metabolism)
  • Carcinoma, Lobular (diagnosis, genetics)
  • Female
  • Humans
  • Immunohistochemistry
  • Observer Variation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: